Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
Upturn AI SWOT - About
SENS 
Senseonics Holdings Inc (SENS)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
10/24/2025: SENS (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
4 Analysts rated it
Very few follow this stock; limited insights, higher-risk early investing.
1 Year Target Price $25.33
1 Year Target Price $25.33
| 1 | Strong Buy |
| 1 | Buy |
| 1 | Hold |
| 1 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit 31.94% | Avg. Invested days 25 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  2.0 | Stock Returns Performance  3.0 |
| Profits based on simulation | Last Close 10/24/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 286.01M USD | Price to earnings Ratio - | 1Y Target Price 25.33 |
Price to earnings Ratio - | 1Y Target Price 25.33 | ||
Volume (30-day avg) 4 | Beta 0.84 | 52 Weeks Range 5.00 - 28.00 | Updated Date 10/25/2025 |
52 Weeks Range 5.00 - 28.00 | Updated Date 10/25/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -2 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Geography
Geography revenue - Year on Year
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin -267.86% | Operating Margin (TTM) -215.42% |
Management Effectiveness
Return on Assets (TTM) -31% | Return on Equity (TTM) -102.61% |
Valuation
Trailing PE - | Forward PE 21.51 | Enterprise Value 270028876 | Price to Sales(TTM) 11.23 |
Enterprise Value 270028876 | Price to Sales(TTM) 11.23 | ||
Enterprise Value to Revenue 10.6 | Enterprise Value to EBITDA 1.76 | Shares Outstanding 40800000 | Shares Floating 37018286 |
Shares Outstanding 40800000 | Shares Floating 37018286 | ||
Percent Insiders 9.03 | Percent Institutions 18.62 |
Upturn AI SWOT
Senseonics Holdings Inc
Company Overview
History and Background
Senseonics Holdings, Inc. was founded in 2006. It focuses on the development and commercialization of continuous glucose monitoring (CGM) systems for people with diabetes. Its key product is the Eversense CGM system.
Core Business Areas
- Continuous Glucose Monitoring (CGM) Systems: Develops and commercializes long-term implantable CGM systems.
Leadership and Structure
The company has a board of directors and an executive leadership team. The CEO leads the organization, responsible for overall strategy and execution.
Top Products and Market Share
Key Offerings
- Eversense CGM System: An implantable CGM system designed to continuously measure glucose levels for up to 180 days. Competitors include Dexcom and Abbott. Limited market share.
Market Dynamics
Industry Overview
The CGM market is growing, driven by increasing diabetes prevalence and technological advancements.
Positioning
Senseonics is positioned as a provider of long-term implantable CGM systems, differentiating itself from competitors who offer shorter-term sensors.
Total Addressable Market (TAM)
The global CGM market is projected to reach over $10 billion. Senseonics aims to capture a portion of this market with its unique product offering.
Upturn SWOT Analysis
Strengths
- Long-term implantable sensor
- Potential for improved patient compliance
- Unique product offering
Weaknesses
- Limited market share
- High cost compared to competitors
- Invasive procedure for sensor insertion
Opportunities
- Expanding partnerships
- Increasing awareness of CGM benefits
- Developing next-generation sensors
Threats
- Competition from established players (DXCM, ABT)
- Reimbursement challenges
- Technological advancements by competitors
Competitors and Market Share
Key Competitors
- DexCom, Inc. (DXCM)
- Abbott Laboratories (ABT)
Competitive Landscape
Senseonics faces strong competition from established players with broader product portfolios and greater market penetration. Senseonics' long-term sensor is a differentiator, but also a challenge because of the invasive nature of the technology and the price.
Growth Trajectory and Initiatives
Historical Growth: Senseonics has experienced fluctuating revenue growth as it commercializes its product.
Future Projections: Analyst estimates vary, with some projecting significant growth driven by increased adoption of Eversense.
Recent Initiatives: Recent initiatives include partnerships for distribution and development of new sensor technologies.
Summary
Senseonics offers a unique, long-term implantable CGM system, differentiating it from competitors. The company faces challenges including a smaller market share, high cost, and the invasive nature of the insertion procedure. Potential growth lies in expanding partnerships, increasing awareness, and developing new sensor technologies. The company is somewhat weak overall, with promising technology held back by practical adoption barriers and competition.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company Filings
- Analyst Reports
- Industry Research Reports
Disclaimers:
This analysis is based on publicly available information and should not be considered financial advice. Market data is approximate and subject to change.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Senseonics Holdings Inc
Exchange NYSE MKT | Headquaters Germantown, MD, United States | ||
IPO Launch date 2016-03-17 | President, CEO & Director Dr. Timothy T. Goodnow Ph.D. | ||
Sector Healthcare | Industry Medical Devices | Full time employees 117 | Website https://www.senseonics.com |
Full time employees 117 | Website https://www.senseonics.com | ||
Senseonics Holdings, Inc., a commercial-stage medical technology company, focuses on development and manufacturing of continuous glucose monitoring (CGM) systems for people with diabetes in the United States and internationally. The company's products include Eversense, Eversense XL, Eversense E3, and Eversense 365, which are implantable CGM systems to measure glucose levels in people with diabetes through an under-the-skin sensor, a removable and rechargeable smart transmitter, and an app for real-time diabetes monitoring and management. It serves healthcare providers and patients through a network of distributors and strategic fulfillment partners. The company was founded in 1996 and is headquartered in Germantown, Maryland.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.